| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T290 |
0-96 |
Sentence |
denotes |
Selinexor is bis(trifluoromethyl)phenyl-triazole-based antineoplastic small molecule (Figure 7). |
| T291 |
97-138 |
Sentence |
denotes |
It was first approved in 2019 by the U.S. |
| T292 |
139-230 |
Sentence |
denotes |
FDA and is being prescribed with dexamethasone for refractory or relapsed multiple myeloma. |
| T293 |
231-372 |
Sentence |
denotes |
Selinexor is an orally bioavailable, selective inhibitor of chromosome region maintenance 1 (CRM1) protein (also known as exportin 1 (XPO1)). |
| T294 |
373-499 |
Sentence |
denotes |
CRM1 is the main export factor that shuttles nuclear proteins to the cytoplasm and is typically overexpressed in cancer cells. |
| T295 |
500-624 |
Sentence |
denotes |
Its selective inhibition can assist in restoring the endogenous tumor-suppressing processes so as to eliminate cancer cells. |
| T296 |
625-908 |
Sentence |
denotes |
Specifically, selinexor selectively and irreversibly modifies the essential Cys528 residue in CRM1, and thus, it blocks CRM1-mediated nuclear export of cargo proteins such as tumor suppressor proteins (p21, p53, pRB, BRCA1/2, FOXO, and others) from the cell nucleus to the cytoplasm. |
| T297 |
909-984 |
Sentence |
denotes |
This leads to the accumulation of tumor suppressor proteins in the nucleus. |
| T298 |
985-1136 |
Sentence |
denotes |
It also results in decreased levels of oncoproteins, cell cycle arrest, and apoptosis of cancer cells without affecting the normal cells [119,120,121]. |
